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EPIGENETIC MODULATION IN BRAF-MUTATED METASTATIC COLORECTAL CANCER 
 
Van Karlyle Morris, M.D. 
Advisory Professor: Scott Kopetz, M.D., Ph.D. 
 
Introduction: BRAF V600E mutations are associated with poor clinical outcomes for patients with 
metastatic colorectal cancer (mCRC).  Unlike other tumors with the same mutation, BRAF 
inhibitors are ineffective as monotherapy.  CRC tumors with BRAF V600E mutations are 
associated with global hypermethylation, which may turn off tumor suppressor gene expression. 
We studied demethylation in BRAF V600E mCRC to restore sensitivity to BRAF inhibitors.   
Methods: Tumor databanks were investigated for genes differentially expressed according to 
BRAF mutation status to identify genes which may be particularly susceptible to epigenetic 
influence.  Mouse xenograft models of BRAFV600E mCRC were treated with vemurafenib or 
azacitidine, alone or in combination, to assess for changes in tumor size.  Tumors and cell lines 
exposed to azacitidine were analyzed for methylation status and for gene expression differences, 
with particular emphasis on genes identified from the bioinformatics analysis. 
Results:  The addition of azacitidine did not restore sensitivity to vemurafenib in two xenograft 
models of BRAF V600E mCRC.  Genes critical to negative regulation of Wnt/β-catenin signaling 
like RNF43 and Axin2 were significantly underexpressed in BRAF V600E mutant tumors when 
compared to their wild-type counterparts.  These genes were hypermethylated in the xenograft 
models, which could be reversed with a demethylating agent.     
Conclusions: The combination of a BRAF inhibitor and a demethylating agent does not appear to 
have promising anti-tumor activity in preclinical models of BRAF V600E mCRC. Negative 
regulators of Wnt/β-catenin signaling are influenced by hypermethylation. Future clinical trials 
incorporating these genes as integral biomarkers should consider gene expression given the 
relevant non-genomic alterations. 
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Chapter I 
INTRODUCTION 
Colorectal Cancer in the United States: Colorectal cancer remains the second leading cause 
of cancer mortality in the United States, with over 50,000 deaths expected in the United 
States in 20161. Over this past several decades, survival for patients with metastatic disease 
has increased due to the incorporation of increased surgical resection for patients with 
oligometastatic disease in which few sites of distant metastases are present2-4. During this time, 
however, there have not been many significant advances with regards to the use of systemic 
agents in the management of metastatic colorectal cancer. Cytotoxic chemotherapies including 
5-fluorouracil/oxaliplatin (FOLFOX) and 5-fluorouracil/irinotecan (FOLFIRI) remain the backbone 
of treatment for metastatic disease5-8. The introduction of biological agents with monoclonal 
antibodies which target VEGF (bevacizumab) and EGFR (e.g., cetuximab and panitumumab) do 
improve survival outcomes further when used in combination with cytotoxic chemotherapy9-14. 
Nonetheless, utilization of such biologic agents must incorporate clinical comorbidities and a 
detailed knowledge of the specific genomic profiling of a given patient. For example, KRAS and 
NRAS mutations, which occur in 45–55% of all patients with metastatic colorectal cancer15-17, are 
contraindications to the administration of anti-–EGFR therapies, as these activating mutations 
occur downstream of EGFR and are associated with inferior outcomes when used in patients 
with RAS-mutated metastatic colorectal cancer9,18-21. 
 
BRAF Mutations in Colorectal Cancer: Valine to glutamic acid substitutions (V600E) in the 
BRAF oncogene occur independently of mutations in KRAS and NRAS22,23. Here, mutations in 
the BRAF oncogene, found in approximately 5-10% of colorectal cancers22, cause constitutive 
activation of the MAPK pathway24-26, which promotes tumor cell proliferation and anti-apoptotic 
activity27.  Along the MAPK signaling pathway, EGFR stimulation triggers activation not only of 
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the separate PI3K/Akt pathway but also of downstream RAS signaling proteins, including 
KRAS and NRAS. Activation of these kinases results in subsequent phosphorylation and 
increased activity of BRAF, which in turn activates MEK1 and MEK2.  These proteins 
subsequently are able to phosphorylate ERK1 and ERK2, which can then be translocated into 
the nucleus in order to propagate the downstream affect her functions of the MAPK signaling 
pathway28. 
 
The BRAF V600E mutation is understood to be an adverse prognostic marker in patients with 
metastatic colorectal cancer29.    Patients with metastatic colorectal cancer who harbor this 
mutation have inferior responses to standard cytotoxic chemotherapy agents relative to their 
BRAF wild type counterparts30-33. In addition, BRAF V600E mutations are associated with unique 
patterns of distant metastatic spread in patients with metastatic colorectal cancer, with higher 
rates of involvement of peritoneum, brain, and bone30. For patients with BRAF V600E mutated 
metastatic colorectal cancer, survival in the metastatic setting has been estimated at only 10 
months, less than the 35 months expected in patients with metastatic BRAF wild-type 
colorectal cancer (BRAFWT-colorectal cancer)30.   
 
BRAF Inhibitors in the treatment of BRAF-mutated colorectal cancer: Unlike metastatic 
melanoma, in which use of targeted inhibitors against the BRAF V600E kinase-like vemurafenib 
and dabrafenib are associated with response rates as high as 50–60 percent34,35, success with 
such agents in the treatment of metastatic colorectal cancer is far inferior. A phase I study of 
vemurafenib noted only one partial response among 21 patients with metastatic BRAF-mutated 
colorectal cancer, for a response rate of 5%36.  A separate phase I/II study of a BRAF 
inhibitor/MEK inhibitor reported similar modest efficacy, with a 12% partial response rate with 
this combination37. These findings suggest that inhibition of the MAPK pathway alone does not 
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adequately inhibit BRAF-mutated colorectal cancer tumor progression. Indeed, subsequent 
preclinical work has shown that inhibition of BRAF by vemurafenib triggers compensatory 
activity of EGFR38,39, which can bypass the inhibited BRAF to trigger downstream PI3K/Akt 
and MAPK signaling. Concomitant inhibition of BRAF and EGFR leads to tumor regression in 
preclinical xenograft models of BRAF mutated metastatic colorectal cancer not seen with 
agents which block BRAF and/or EGFR alone. Translating these findings into the clinical 
setting, early results from phase I/II clinical trials provide promising data that this approach 
may have some success in the treatment of BRAF mutated metastatic colorectal cancer. 
Nonetheless, resistance to target therapies invariably develops, and additional understanding 
is required in order to deep in the antitumor response40. Understanding better the complex 
biology underlying these tumors is essential in order to design improved treatment options for 
this subset of patients. 
 
Hypermethylation in BRAF-mutated colorectal cancer: Analysis of 239 tumors from The 
Cancer Genome Atlas (TCGA) revealed that BRAF mutations occur predominantly within a 
subpopulation of colorectal cancer that is characterized by a high genomic mutational burden, 
a phenotype which is also observed with the presence of microsatellite instability41. In 
colorectal cancer, microsatellite instability leads to deficient mismatch repair of DNA and can 
be caused either by germline mutations in critical DNA mismatch repair proteins or by tumor 
hypermethylation42,43.  Here, promoter hypermethylation of the MLH1 gene leads to 
downstream silencing of this gene and lack of activity of this critical DNA mismatch repair 
protein. 
Hypermethylation in colorectal cancer is associated with the CpG Island methylation 
phenotype (CIMP). The vast majority (>90%) of BRAF-mutated colorectal cancer is CIMP- 
positive and features promoter regions of DNA enriched with cytosine-guanine (CpG) 
dinucleotides44,45.  Hypermethylation of tumor suppressor genes leads to gene silencing and 
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loss of cell cycle regulation, among other functions46,47.  Without concurrent hypermethylated 
genomes, BRAF-mutated colonocytes remain senescent48-50. Together, BRAF mutation and 
hypermethylation comprise key molecular features of the “serrated adenoma” pathway to 
colorectal cancer tumorigenesis51,52, which is named for the unique precursor lesion, 
highlighting the key role of epigenetics in the pathogenesis of BRAF-mutated colorectal 
cancer. 
 
Wnt/β-catenin signaling in metastatic colorectal cancer: Alterations of the Wnt/-catenin 
pathway are present in >90% of colorectal cancers41, and inhibition of this pathway remains 
the "holy grail" for targeted therapies in this disease. Inactivating mutations in APC and 
activating mutations in CTTNB1 account for the majority of these alterations53, and are 
difficult to target pharmacologically54. The remaining fraction of colorectal cancer tumors are 
wild-type (WT) for APC and CTTNB1 and often feature aberrancies in tumor cell surface 
proteins like RNF43 and R-spondin (RSP0)55, which also lead to deregulated Wnt/-catenin 
signaling56,57. These tumors derive predominantly from the sessile serrated adenoma 
pathway and have a high proportion of BRAF mutations. 
 
Wnt/ β -catenin signaling is important in the pathogenesis of colorectal cancer. Most 
colorectal tumors are driven by aberrant Wnt signaling predominantly via APC and CTTNB1 
mutations58,59.  RNF43 mutations and RSPO fusions have been found in approximately 20% 
of colorectal cancer tumors and are exclusive to APC and CTTNB1 mutations. The common 
endpoint of these irregularities is nuclear translocation of β-catenin and upregulation of the T-
cell factor transcriptional complex, promoting cell proliferation, anti-apoptotic behavior, and 
the epithelial-to-mesenchymal phenotype60,61. 
 
Preclinical work has suggested that targeted agents can dampen Wnt/-catenin signaling in 
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colorectal cancer models harboring RNF43 mutations or RSPO fusions62. However, 
additional alterations, including epigenetic modulation, also activate Wnt signaling in a ligand 
dependent manner in a subset of patients. Predictive biomarkers with available matched 
targeted therapies against Wnt/-catenin signaling are needed in order to tailor novel agents 
for patients with metastatic colorectal cancer. 
  
6 
 
CHAPTER II 
METHODS 
Xenograft Studies 
Tumors were collected under an IRB-approved protocol from 2 patients with BRAF–mutated 
metastatic colorectal cancer who were treated at M.D. Anderson for establishment of patient-
derived xenografts.  The specimens were called “C0999” and “B1003” in order to provide names 
for these models that included no personally identifiable patient information. These xenograft 
tumors had been previously established by our group and were removed from storage at -80° 
Celsius. The samples were thawed, and for each of the 2 models individually, the thawed tumor 
was divided by scalpel at room temperature into 10 equal parts for an approximate volume of 4 
x 4 x 4 mm. These smaller tumors were implanted subcutaneously into the right lateral flank of 
10 individual female, NOD–SCID–gamma mice (purchased from Experimental Radiation 
Oncology at M.D. Anderson).   
Once it had been determined that the tumors were growing in the mice in which they had been 
implanted, for each of the 2 different models, 6 mice were selected for further use once their 
mean tumor volume was approximately 200 mm3.  These 6 mice were randomized into 3 equal 
arms (N=2 per arm) for initial treatment randomization. Here, an F1 generation was treated 
intraperitoneally with placebo (phospho-buffered saline, Sigma Aldrich) or with 5–azacitidine 
(Sigma Aldrich) at 2 different doses (0.25 mg/kg or 0.50 mg/kg).  Intraperitoneal injections were 
administered twice weekly. The F1 generation was utilized to allow for prolonged exposure a 
demethylating agent prior to the experimental studies regarding a BRAF inhibitor in the F2 
generation. Once these 6 tumors had reached a mean volume had reached a mean volume of 
1500 mm3, the mice were sacrificed, and the tumors were harvested. Here, the tumors were 
immediately divided using a scalpel into equal parts with approximate volumes of 4 x 4 x 4 mm.  
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Tumors from the placebo/control mice in the previous F1 generation were implanted into 30 
female NSG mice, and tumors from the 5–azacitidine treated mice were implanted into 30 
different female NSG mice. Given that toxicities appeared to be similar/insignificant between the 
mice in the F1 generation treated with azacitidine at doses of 0.25 mg/kg and 0.50 mg/kg, we 
chose to continue with the tumors that had been exposed to azacitidine at a dose of 0.50 mg/kg 
for the experimental studies as part of the F2 generation. We surmised that doing so would 
optimize the exposure to a demethylating agent. 
For the 2 sets of mice in the F2 generation which were treated with saline/placebo or 
azacitidine, they continue to 
receive twice-weekly 
intraperitoneal injections until 
the mean tumor size was 
approximately 200 mm3.  At that 
time, mice were randomized in 
a 1:1 fashion to receive or not to 
receive concomitant 
vemurafenib (see Figure 1 for 
experimental flow).  Vemurafenib was administered continuously as a chow at a dose of 417 
mg/kg (Plexxikon/Scientific Diets), and control chow was provided by scientific diets as well.  
This resulted in 4 different groups for analysis: untreated control, azacitidine only, vemurafenib 
only, and azacitidine plus vemurafenib. Tumor volumes were measured twice-weekly and 
calculated as the product of length2 x width/2, whereby length represents the longest axis of the 
cross-sectional measurements of the particular tumor.   
The primary endpoint here was tumor size after a five-week treatment period, and the primary 
objective was to assess if the combination treatment resulted in smaller tumor size compared to 
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BRAF inhibitor treatment alone. For the primary comparison of tumor size at 5 weeks, we fit a 
one-way ANOVA model to assess the difference among all four treatment groups in order to 
derive the pairwise comparison results. 
Bioinformatic Analysis  
The CIMP-High status and the BRAF mutation data of the TCGA CRC samples were extracted 
from the Memorial Sloan Kettering Cancer Center cBio portal (www.cbiopartal.org). The 36 
corresponding CIMP-High samples were only retained in the RNAseq and Methylation datasets, 
and BRAF mutation status was identified from the identified samples.  Probes/genes were 
queried from the 450,000 probes provided by the Illumina 27K methylation assay (Illumina, San 
Diego, CA) to compare the BRAF wild-type and mutated populations.  From these cases, 
univariate analysis was performed to identify differentially expressed transcripts and 
differentially methylated transcripts using t-test from the various probes of interest. The p-values 
obtained by multiple t-tests were corrected with a false discovery rate using the beta-uniform 
modeling (BUM) method. The same methodology strategy was performed using the available 
data internally from the MD Anderson Integromics dataset.   Again, RNAseq datasets were 
analyzed according to BRAF mutant and BRAF wild-type specimens from patients with 
colorectal cancer.  Given the higher number of gene expression differences in various gene 
probes for this dataset, we constructed a heat map to illustrate the differences in expression 
patterns between these two populations of interest.  Lists of genes with differential expression 
were compared for the two independent analyses to provide a better validated identification of 
genes which may be preferentially overexpressed (or underexpressed) in the BRAF-mutant 
CRC population.  The list of genes identified here was used as input into the IPA Ingenuity 
BioProfiler list (www.ingenuity.com) to identify signaling pathways which may be most 
influenced by the variations in gene expression for the selected genes of interest from the  gene 
expression analysis. 
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Methylation Profiling of Xenograft Tumors 
We were interested as well in comparing the methylation profiling of the xenograft tumors 
exposed or not exposed to azacitidine.  Here, 15 xenograft tumors were analyzed – 7 control 
tumors (4 from B1003 and 3 from C0999) and 8 experimental (3 from C0999 and 5 from 
B1003).  Frozen tumors stored at -80°C were thawed, and DNA was extracted and isolated 
using a DNeasy Blood and Tissue kit (Qiagen, Valencia, CA). To check the overall methylation 
pattern 10,000 highly variable probes were chosen from the Illumina 450k dataset. A next 
generation heat map was generated using the highly variable probes for visualization. 
To test whether or not azacitidine was successful in demethylating biologically relevant markers 
for the presence of CIMP, three genes commonly hypermethylated in CRC tumors and 
universally accepted as markers for the presence of CIMP-high status – CACNA1G, RUNX3, 
and TIMP3 – were selected for further study.  Here, mean methylation values (with associated 
standard deviation) from the 5’-methylation probe for each of the individual genes were 
calculated for the C0999 and B1003 tumors in the control and experimental/azacitidine arms.  
Results were compared between control and experimental arms each of the two xenograft 
models separately using a t-test in order to examine whether or not a difference in methylation 
was noted for the tumors exposed to a demethylating agent. 
Given that the Wnt/β-catenin signaling pathway had been demonstrated to be preferentially 
affected for BRAF mutant versus wild-type tumors, various genes in this pathway were also 
selected to assess for differences in methylation between the control and experimental/ 
azacitidine groups for the C0999 and B1003 models separately.  Here, the following genes were 
examined: APC2,   AXIN1, AXIN2, CSNK1A1, CSNK1D, CSNK1E, CSNK1G1, CSNK1G2 
CSNK1G3, DVL1, DVL2, DVL3, FZD1, FZD2, FZD3, FZD5, FZD6, FZD8, FZD9, FZD10, 
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GSK3A, GSK3B, LRP1, LRP4, LRP5, LRP6, RNF43, and RSPO1.  Results were compared 
separately using a t-test for each of the given genes. 
Gene Expression Profiling of BRAF-mutated CRC Models 
To test further whether or not differences in gene expression were noted by the use of 
azacitidine, we first extracted RNA (Qiagen RNeasy kit) from the same xenograft tumors which 
had been analyzed for methylation for the C0999 and B1003 models.  We were interested in 
looking at the genes in which methylation differences had been noted between the control and 
experimental (azacitidine-treated) arms in the xenograft studies to see if a corresponding 
differential gene expression possibly affected by methylation was observed.   Once isolated, 
RNA was assessed by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) 
with probes specific for selected genes (APC2, AXIN1, AXIN2, CSNK1A1, CSNK1D, FZD9, 
LRP1, LRP4, LRP5, RNF43).   Mean expression levels for the selected genes were compared 
between control tumors and experimental tumors for each of the two xenograft models.  To look 
at another data set, we had gene expression data generated from prior work with the 
BRAFV600E CRC cell line HT29 treated with and without a demethylating agent.   Cells were 
treated for 14 days with or without azacitidine, and harvested for RNA to compare differences in 
gene expression of selected genes.  qRT-PCR was performed using probes from the same 
genes in the Wnt/β-catenin signaling pathway as listed above.   Differences between control and 
experimental/treated cells were compared using a Student’s t-test. 
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CHAPTER III 
RESULTS 
Xenograft Studies 
Two different xenograft models of BRAF–mutated metastatic colorectal cancer – C0999 and 
B1003 –were utilized for these experiments to assess whether or not the addition of azacitidine 
to vemurafenib generates additional tumor regression. The results are seen in Figures 2 and 3.  
In both experiments, 40 mice with established C0999 or B1003 BRAF–mutated metastatic 
colorectal cancer xenografts were divided into 4 separate arms of 10 mice each. Mice were 
treated as either untreated controls, or with vemurafenib, azacitidine, or the combination of 
vemurafenib plus azacitidine. As seen in Figure 2, which represents the C0999 xenograft model, 
the addition of vemurafenib, with or without azacitidine, generated a significant tumor 
regression, with no 
palpable tumor in either 
arm, after 21 days of 
treatment. However, 
these tumors quickly 
grew back with no 
persistent response to 
BRAF inhibition.  
ANOVA analysis was used to demonstrate that a significant difference (P < .0001) in tumor 
volume at day 28 was detected among before groups here. Specifically, although there were no 
differences in tumor volume between control/azacitidine groups and vemurafenib/vemurafenib 
plus azacitidine groups, there were differences between the 2 groups of mice which received 
vemurafenib in the 2 groups of mice which did not receive vemurafenib. 
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In Figure 3, the growth curves for the B1003 BRAF mutated metastatic colorectal cancer 
xenograft model are shown, with individual arms for the untreated control, vemurafenib, 
azacitidine, and 
vemurafenib plus 
azacitidine 
combination 
groups. Unlike 
the prior 
xenograft model, 
ANOVA analysis 
demonstrated no difference in tumor sizes between the four groups here (P=.66). For all 
cohorts, the tumors demonstrated no regression noted for any of the mice treated with 
experimental agents. 
Collectively, for both xenograft models used here, C0999 and B1003, azacitidine did not cause 
regression in mean tumor volume, independent of inhibition of BRAF with vemurafenib. 
Bioinformatic Analysis of Gene Expression/Methylation Patterns 
In order to perform differential expression analysis between the BRAF mutant and wild-type 
sample groups in the RNAseq and methylation data of TCGA CRC dataset, we examined 226 
samples with RNAseq and Methylation datasets both available. Of these 226 samples in this 
dataset, 36 samples were in CIMP-High group. Sixteen were BRAF mutated, and twenty were 
BRAF wild-type.  With a False-Discovery Rate (FDR) threshold of 0.3, there were 55 
significantly different transcripts in the RNAseq data (see Figure 4A) within the CIMP-high group 
distinguished according to BRAF mutation status.   Even with an FDR threshold of 0.3 there 
were no significant probes in the methylation data (Figure 4B).   
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We next turned to the Integromics cohort of patients at MD Anderson, a separate group of 
patients independent from 
the samples analyzed in the 
TCGA, for whom genomic 
(mutation) profiling, RNAseq 
gene expression data, and 
methylation data had already 
been characterized.  Here we 
performed hierarchical 
clustering using a heat map 
generated by the gene expression data, and analyzed according to BRAF mutation status.  As 
seen in Figure 5, a clear difference in selected genes was noted for patients in this cohort 
according to BRAF mutation status.  There were 5954 genes which demonstrated differential 
gene expression according to BRAF mutation status in the analysis of the RNAseq gene 
expression data for the Integromics 
cohort.  CIMP high vs CIMP low 
status was not available to select 
only for the CIMP-high patients, as 
had been done in the analysis of the 
TCGA data.  Genes of interest 
which  were preferentially 
underexpressed for the BRAF-
mutated population relative to the 
BRAF wild-type population in the 
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Integromics cohort (with adjusted p-value to quantify the significance of difference) include 
AXIN2 (2.8 x 10-13), FOXD1 (5.2 x 10-13),  RNF43 (1.3 x 10-12), MLH1 (2.8 x 10-11), PTPRD (3.7 x 
10-12), JUN (5.9 x 10-9), RBP2 (1.4 x 10-8), APC2 (4.9 x 10-8), and RNF44 (1.1 x 10-6). 
 
Next, we were interested in identifying the union genes which were differentially expressed 
according to BRAF mutation status for both the Integromics and TCGA separate cohorts.  We 
compared the 250 genes of highest significance of difference for each of the two datasets and 
identified genes common to both lists.  These genes are listed in Table 1 below, along with the 
direction of change of gene expression (overexpressed or underexpressed) of the BRAF-
mutated patients relative to the BRAF wild-type population: 
 
Gene Relative expression in 
BRAF-mutated cohorts 
Function of gene 
AXIN2 Underexpressed Phosphorylates CTTNB1 in 
preparation for degradation 
EPDR1 Underexpressed Cell-ECM adhesion 
KHDRB53 Underexpressed Inhibits cell proliferation 
RNF43 Underexpressed Negative regulator of 
Wnt/beta-catenin signaling 
MLH1 Underexpressed Mismatch repair of DNA 
RAB32 Underexpressed Binds to regulatory unit of 
PKA 
TDGF1 Underexpressed Cripto1:EGF signaling 
KDSR Overexpressed Sphingosine/ceramide 
synthesis 
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Gene Relative expression in 
BRAF-mutated cohorts 
Function of gene 
JUN Underexpressed  
GTF21RD1 Underexpressed Transcriptional regulator 
under control of Rb 
PTPRO Underexpressed Induced by  Wnt signaling; 
negative regulator of 
Wnt/beta-catenin signaling 
PLAGL2 Underexpressed Inhibits differentiation to 
generate stem cell phenotype; 
upregulates Wnt signaling 
RBP2 Underexpressed Retinal-binding protein 
TDGF3 Underexpressed  
ID1 Underexpressed Inhibitor of DNA binding 
DDX27 Underexpressed RNA helicase involved in 
cellular growth/differentiation 
HPSE Overexpressed Facilitates cell migration via 
ECM degradation; cleaves 
HSPGs 
IHH Underexpressed Indian hedgehog 
LM04 Overexpressed Transcription factor  for 
oncogene activity 
ZIC5 Overexpressed DNA binding, activation of 
transcription factors 
CYP2B6 Underexpressed Retinoic acid  production 
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Gene Relative expression in 
BRAF-mutated cohorts 
Function of gene 
FERMT1 Underexpressed Links extracellular matrix to 
cytoskeleton 
NR1I2 Underexpressed Binds CYP3A4 and RXRA 
GPR56 Underexpressed Cell adhesion; in melanoma, 
overexpression inhibits 
metastases 
MOSC2 Overexpressed  
GRAMD1A Underexpressed  
KDELR3 Overexpressed Golgi: ER processing 
TINAG Underexpressed  
SPATA2 Underexpressed  
SEC22B Overexpressed  
 
Table 1: Genes preferentially expressed (direction of change listed in middle column) for 
BRAF-mutated CRC tumors in the Integromics cohort and the TCGA cohorts, with 
description of the functional relevance of selected genes in the third column. 
 
With many genes here demonstrating differential gene expression among the BRAF mutated 
and BRAF wild-type cohorts, we were next interested in understanding what signaling pathways 
may be preferentially affected by the presence or absence of a mutated BRAF. We performed 
an Ingenuity IPA pathway analysis incorporating the identified genes, common to both the 
TCGA and Integromics data sets, with the results for the most significant signaling pathways 
listed in Figure 6: 
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One of the strongest links was in genes affecting “colorectal cancer metastasis signaling,” which 
serves as a confirmatory positive control for the biological relevance of this analysis here.  Other 
pathways of interest included pathways involved in inflammation/immune activity (“role of 
macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis,” “granulocyte adhesion 
and degradation,” “natural killer cell signaling,” and “B cell receptor signaling”).  Of great 
interest, the Wnt/β-catenin signaling pathway was also associated with preferential activity in the 
BRAF-mutated colorectal cancer cohorts per the results of this pathway analysis. 
 
Methylation Profiling of Xenograft Tumors 
Given that no significant differences in tumor volumes were noted in the xenograft studies with 
the use of a demethylating agent, we next performed methylation profiling for the various tumors 
treated with or without azaciditine to assess whether or not changes in methylation were 
occurring.  To check the overall methylation pattern 10,000 highly variable probes were chosen 
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from the Illumina 450k dataset.  The next generation heat map from this analysis is 
demonstrated in Figure 7. 
 
Clearly, for the C0999 and B1003 models alike, profiles for methylation are very similar. In this 
figure, red represents an overall lower degree of methylation, whereas the whiter hue 
represents a higher level of methylation. In the untreated controlled groups, for both xenograft 
models, for the selected probes there is a methylation profiling which demonstrates clear higher 
levels of methylation overall relative to the 2 groups (C0999 and B1003) which were exposed to 
azacitidine.  In addition, the individual xenograft tumors treated with azacitidine clustered 
together between the individual models. In other words, all of the C0999 xenograft tumors that 
were treated with azacitidine had a methylation profiling that was separate and distinct from the 
B1003 xenograft tumors that were treated a demethylating agent.  These results lend support to 
the notion that azacitidine was indeed capable of performing his task in the xenograft tumors – 
i.e., reversing methylation of specific genes.  Therefore, it cannot be concluded that no 
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differences in tumor volumes were observed due to the lack of demethylation by azacitidine. 
Instead, this drug was able to alter the overall methylation patterns within the given tumor. 
We also looked at genes which are known to be under epigenetic regulation and, when 
methylated, characterize the presence of CIMP–high status for a given tumor. Specifically, we 
looked at the 3 genes CACNA1G, RUNX3, and TIMP3.  As seen in Figure 8, for both xenograft 
models, the addition of azacitidine resulted in a significantly lower degree of methylation in the 
experimentally treated group when compared to the untreated controls.  This provided additional 
evidence to us that the administration of a demethylating agent resulted in changes in 
methylation profiling and serves as a positive pharmacodynamics biomarker that azacitidine 
was indeed performing its specified task in these studies (P< .005 for all six comparisons). 
 
 
Methylation/gene expression analysis of Wnt/β-catenin targets 
The Wnt/β-catenin signaling pathway was a pathway previously identified to show differential 
gene expression for colorectal tumors according to the presence or absence of a BRAF 
mutation.  We next proposed to examine specific genes of interest in this pathway in order to 
assess whether their expression may be affected by demethylation.  Specifically, we compared 
methylation levels between untreated control groups and their corresponding azacitidine groups 
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for each of the two xenograft models for the following genes: Axin1, Axin2, APC2, CSNK1A1, 
CSNK1G2, CSNK1D, FZD9, FZD1, LRP4, and LRP5.  Statistically significant changes in 
methylation (P<.05 for all) were noted with the addition of a demethylating agent, as seen in 
Figure 9: 
 
Here, methylation levels of genes like Axin2, CSNK1A1, Fzd9, Fzd1, and Lrp4 were reduced in 
both models of BRAF-mutated metastatic colorectal cancer with the addition of azacitidine, 
whereas higher methylation of Axin1 and APC2 were noted with the same intervention. 
Comparison of Gene Expression Profiling of selected genes in the Wnt/β-catenin 
signaling pathway for the Xenograft models of BRAF-mutated colorectal cancer 
Given that we found significant differences between the various previously mentioned genes in 
this signaling pathway, we next analyzed gene expression profiling on the xenograft tumors 
individually and compared the mean values between the control groups and the azacitidine 
groups to assess whether or not these changes in methylation correlated to matched changes in 
gene expression profiling.  Table 2 lists the magnitude of change (ratio) of the mean level of 
gene expression by RNAseq for the azacitidine group relative to that of the untreated control 
group. In all instances, a t-test was performed to compare the mean values the P value to 
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compare for a difference between the untreated control and the experimental groups exceeded 
0.05, and therefore none of the differences noted were statistically significant for these 
experiments. 
Here, the direction of change for CSNK1A1, CSNK1D, Fzd9, and Fzd1 were all increased, 
which corresponded to the direction of change for the matched change in methylation noted by 
the addition of azacitidine in the respective experiments, which was decreased.  Therefore, the 
methylation changes were biologically consistent with the changes in the gene expression. 
Gene C0999 B1003 
Axin1 1.21 .93 
Axin2 1.16 .76 
APC2 4.02 1.22 
CSNK1A1 1.07 1.34 
CSNK1D 1.00 1.04 
Fzd9 25.7 1.37 
Fzd1 1.09 1.79 
Lrp4 1.00 .73 
Lrp5 1.12 .97 
 
Table 2: Magnitude of change in mean gene expression of various genes in Wnt/β-
catenin signaling upon addition of azacitidine. 
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qRT-PCR Analysis of BRAF-mutated xenograft models  
To investigate further whether or not there were differences in gene expression upon the 
addition of azacitidine for the C0999 and B1003 models, we performed quantitative reverse-
transcriptase PCR (qRT-PCR) on frozen specimens of xenograft tumors in the untreated 
controls and in the cohort exposed to azacitidine.  Mean values (with standard error) are 
demonstrated for each of these genes in Figure 10:  Here, no significant changes in gene 
expression according to qRT-PCR were noted in any of the genes assessed in this pathway 
with the exception of RNF43 in the B1003 model, whose expression did increase upon 
exposure to azacitidine.  Interestingly, RNF43 was also the gene with the strongest association 
with preferentially decreased expression in the gene expression profiling for the BRAF-mutated 
colorectal tumors relative to the BRAF wild-type tumors.  
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qRT-PCR Analysis of BRAF-mutated cell line models We also looked at the HT29 BRAF–
mutated colorectal cancer cell line for changes in methylation and in gene expression upon the 
introduction of azacitidine. Here, we compared mean values for differences in methylation and 
in gene expression for untreated controls versus cells treated with a demethylating agent using 
qRT-PCR provided from an outside, publicly available data set.    Table 3 demonstrates the 
magnitude of change in the ratio is for both methylation and corresponding gene expression in 
mean is azacitidine: untreated control for each of the listed genes important in the signaling 
pathway. Values with significant differences are listed, but otherwise only trends, but no 
statistically significant differences, were observed upon the addition of azacitidine.  Notably, 
decreases in mean levels of methylation were observed for Fzd9 and Lrp4 with an associated 
increase in gene expression upon addition of azacitidine.  Increases in methylation were 
likewise observed with Axin1 and Lrp5 with associated decrease in gene expression of these 
genes. In addition, expression of the surface proteins RSPO2 and RSPO4 were observed upon 
exposure to azacitidine, and neither of these genes were expressed at detectable levels by 
qRT-PCR in the untreated control HT29 cells. 
Gene Methylation change RNAseq change 
(for azacitidine) 
Axin1 ↑ ↓ (P=.04) 
Axin2 ↓ ↑ 
APC2 ↑ ↑ 
CSNK1A1 ↓ ↓ 
CSNK1D ↓ ↓ 
Fzd1 ↓ ↑ (P=.03) 
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Gene Methylation change RNAseq change 
(for azacitidine) 
Fzd9 ↓ ↑ 
Lrp4 ↓ ↑ (P=.06) 
Lrp5 ↑ ↓ (P=.04) 
RNF43 ↓ ↓ 
RSPO2  ↑ (0 -> detected) 
RSPO 4  ↑ (0 -> detected) 
 
Table 3: Direction of change in mean methylation and gene expression of various genes 
in Wnt/β-catenin signaling upon addition of azacitidine in HT29 BRAF-mutated colorectal 
cells. 
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CHAPTER IV 
DISCUSSION 
BRAF–mutated metastatic colorectal cancer represents a rare subset of the colorectal cancer 
population with characteristic clinical and pathological features. Notably, these tumors are 
associated with concomitant microsatellite instability and global hypermethylation.  As patients 
whose colorectal tumors harbor these BRAF V600E mutations demonstrate poor responses to 
standard cytotoxic chemotherapy regimens and rapid clinical deterioration that lead to terrible 
survival outcomes, new therapies are desperately needed in order to provide this group of 
patients otherwise effective treatment. This proposal sought to address the role of 
hypermethylation in these BRAF mutated colorectal tumors by a set seeing the role of a 
demethylating agent in combination with a BRAF inhibitor and by identifying signaling 
pathways/potentially targets which have the potential to be manipulated by demethylating 
agents. 
Azacitidine is a nucleoside analogue which forms covalent bonds with DNA methyltransferases 
and inhibits further methylation of downstream nucleotides, thereby promoting an overall 
demethylated state63.  Demethylating agents have FDA–approval for clinical use in hematologic 
disorders such as myelodysplastic syndrome. However, the clinical utility of azacitidine in solid 
tumors is less understood. Preclinical studies have shown that brief exposure of epithelial tumor 
cell lines to low doses of demethylating agents generates a sustained anti-tumor effect, even 
against subpopulations of solid tumors not sensitive to standard chemotherapy64.  These 
findings provided us with the rationale to study lower doses of azacitidine over prolonged 
treatment time with the goal of understanding whether or not demethylation can restore 
sensitivity to BRAF inhibitors in preclinical models of colorectal cancer. 
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We examined two xenograft models of BRAF mutated metastatic colorectal cancer to 
investigate the interplay between BRAF inhibitors and demethylating agents.  To our surprise, 
the C0999 model showed sensitivity to single agent therapy with the BRAF inhibitor 
vemurafenib. Here, after approximately 3 weeks, all tumors developed complete regression with 
this therapy. Eventually, all tumors treated with the BRAF inhibitor develop resistance to this 
therapy, and detailed analysis of these findings was performed and has been described 
elsewhere (manuscript under review). Our conclusions, based on mutational profiling at the time 
of acquired resistance, were that these tumors were dependent on continued MAPK signaling 
as a means to propagate tumor growth. Regardless, in both the C0999 model and the B1003 
model, the addition of azacitidine had no effect on treatment response/tumor volume either by 
itself or in combination with vemurafenib. 
Given these findings, we were interested in understanding whether or not these azacitidine was 
even affecting methylation patterns at the low dose at which was being administered. To assess 
this further, we performed genomic methylation profiling on the tumors in the control arms and in 
the tumors treated with a demethylating agent. Clearly, differential methylation profiling was 
seen in the tumors that were treated with azacitidine.  Some of the methylation probes were 
noted to be hypermethylated in the control tumors and then convert to a less methylated state 
upon exposure to azacitidine, whereas other probes were noted to be more demethylated in the 
control and become more methylated with the addition of azacitidine.  Notably, many of the 
latter cases happen to be probes that were assessing methylation within the bodies of genes of 
interest (downstream from the 5’-promoter sequence).  On the other hand, many of the probes 
which were relatively more methylated in the control group were found on the 5’-promoter foci.  
Previous work on the X-chromosome studying the relationship between epigenetic modulation 
and gene expression has shown that, in genes which are actively express, an inverse 
relationship exists in methylation patterns between the promoter sequence and gene body 
28 
 
sequence65. In other words, decreased methylation at the promoter site with corresponding 
relative hypermethylation at the gene body can be associated with higher levels of gene 
expression. Alternatively, higher methylation levels in the promoter region with corresponding 
lower methylation patterns in the gene body sequence can be associated with relatively lower 
levels of gene expression. These patterns could explain why there were regions of both 
hypermethylation and relative hypomethylation in the xenograft tumors randomized to the 
control arm, which were reversed with use of a demethylating agent. As evident by our data, 
methylation patterns were reversed by azacitidine. Despite the fact then that there was no 
change in tumor volume with the addition of azacitidine, this drug was nonetheless 
pharmacodynamically effective in reversing methylation patterns with the use of a lower dosed, 
prolonged exposure to a demethylating agent treatment strategy. 
Next, we were interested in identifying genes which may be preferentially affected by 
methylation changes in the BRAF mutated colorectal cancer population relative to the BRAF 
wild type counterparts. Based on gene expression characterization, genes like MLH1 were 
preferentially under expressed in the BRAF mutated population. Decreased expression of this 
gene is associated with deficient mismatch repair in colorectal cancer43,66, and, given that BRAF 
mutations are likewise associated with microsatellite instability, this findings served as a positive 
control that provided validation to our data within the correct clinical context for the biologic 
understanding of colorectal cancer. Interestingly, two of the most significantly underexpressed 
genes in the BRAF–mutated population were AXIN2 and RNF43. Both of these genes serve as 
negative regulators of Wnt/β-catenin signaling, and, when not fully present, can be associated 
with increased activity of this pathway which is seminally important in the pathogenesis of 
colorectal cancer.  RNF43 mutations often occur mutually exclusively to APC mutations55, and 
appear to co-occur more commonly with BRAF mutations (unpublished data estimated RNF43 
mutations present in 64% of BRAF mutated colorectal tumors).  This protein is found at the 
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surface of the tumor cell and functions to downregulate the presence of the Wnt ligand receptor 
Frizzled (Fzd).  Similarly, AXIN2 is also important in modulating activity of the Wnt/β-catenin 
pathway.  Lower expression levels of this gene prevent APC binding to and eventual 
phosphorylation/degradation of β-catenin, thereby permitting continued effector activity upon 
nuclear translocation of β-catenin. Given that these were two of the strongest associations for 
preferential gene under expression and given that we know that Wnt/β-catenin signaling is 
deregulated in greater than 90% of colorectal cancers41, even in the absence of an APC 
mutation, we were next interested in investigating whether or not non-APC genes may be 
susceptible to the effects of epigenetic modulation in Wnt/β-catenin signaling via changes in 
methylation. 
For both xenograft models, AXIN2 was relatively over methylated in the untreated controls, and 
methylation levels at the 5’-promoter and were significantly reversed from a hyper-methylated 
state. This was also seen in other tumor suppressor genes imported in Wnt/β-catenin signaling 
like APC2, FZD9, and LRP4.  Corresponding gene expression profiling differences were noted 
in FZD9 (25.7x) and APC 2 (4.02x) were noted with corresponding reversal in methylation by 
azacitidine in both xenograft models. However, no statistically significant differences were noted 
despite the high differential magnitude of these trends, which may have been statistically limited 
by the low number of tumor specimens that were able to be assessed by this project. To 
investigate further, we performed RT–PCR on RNA extracted from both control and 
experimentally treated xenograft tumors to assess for any differences in gene expression using 
a different methodology. Interestingly, RNF43 was preferentially increased in terms of gene 
expression in the B1003 model that was exposed to azacitidine. Using a different model, an 
HT29 BRAF–mutated colorectal cancers line, use of a deep bleeding agent was associated with 
a decrease in methylation profile with corresponding trend towards increase in gene expression 
for genes like AXIN2, FZD1, LRP4, and LRP5.  Collectively, these findings may suggest that 
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negative regulators important in Wnt/β-catenin signaling may be influenced by epigenetic 
modifications in methylation, and have the potential to be targeted in the future. 
The implications of these findings are important when translating towards clinical applications. A 
recent phase II clinical trial assessing the addition of a porcupine inhibitor to agents against 
BRAF and EGFR completed for patients with BRAF mutated metastatic colorectal cancer 
harboring concomitant RNF 43 mutations.  While current clinical trials often consider only 
genomic aberrations (e.g., mutations) in determining inclusion criteria for assessing tumors with 
a targetable drug against a known/defined aberrant signaling pathway, our data suggest that 
non-genomic/epigenetic aberrations, and their corresponding influence on the pathogenesis of a 
given tumor, should be considered as well when seeking to identify patients who may benefit 
from a novel therapeutic agent under study. From our results, given that methylation can be 
associated with potential gene expression, we support the idea that gene expression profiling 
may better include patients with aberrant Wnt/β-catenin signaling of interest in future clinical 
trials. 
  
31 
 
Chapter V 
LIMITATIONS 
We did not see any antitumor response with the addition of a demethylating agent to treatment 
with a BRAF inhibitor. However, since the time that this experimental design was planned, 
preclinical work has shown that inhibition of BRAF in the BRAF–mutated colorectal cancer is 
associated with an upregulation in EGFR, and that antitumor responses can be restored with 
the addition of an anti-–EGFR therapy. Clinical trials that are currently ongoing will provide 
additional insight into the efficacy of combined targeted therapies against both BRAF and 
EGFR. Given this updated knowledge, the more clinically applicable experimental design would 
have been to test the addition of azacitidine to therapies targeting both BRAF (vemurafenib) and 
EGFR (cetuximab).   
Although trends were seen in differential gene expression by both RT–PCR of RNA extracted 
from xenograft models treated with azacitidine and from cell line models of BRAF mutated 
colorectal cancer treated with azacitidine, no statistically significant differences were detected. 
Given the finding that was available for this project from the ASCO Young Investigator Award, 
we were able to perform analyses only on a few selected tumors. The trends that we observed 
may have been limited by high standard deviations reflective of a low sample size. Increasing 
the sample size and including additional tumor samples may have detected statistically a 
difference back only be inferred at present with the current trends. 
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Chapter VI 
FUTURE DIRECTIONS 
We are collaborating with a company in the Texas Medical Center who has created a novel 
inhibitor of Wnt/β-catenin signaling whose activity is very downstream in the nucleus. Given that 
we have this increased understanding of the role of this pathway that it is important and BRAF 
mutated colorectal cancer pathogenesis based on these data, we would like to test this in 
combination with targeted therapies against both BRAF and EGFR in preclinical xenograft 
models. If promising activity is observed, then we propose translating these findings into a 
clinical trial. 
We are also set to open a clinical trial at M.D. Anderson in the coming months which 
incorporates an antibody against RSPO, another regulator important in signaling of the Wnt/β-
catenin pathway, in combination with the cytotoxic chemotherapy regimen FOLFIRI.  Inclusion 
criteria for the study will build upon our conclusion here that patients must have high levels of 
expression of RSPO in order to be candidates for the dose expansion portion of the study. 
Therefore, gene expression profiling will be incorporated into the screening process. 
 
  
Formatted: Font: Bold
33 
 
REFERENCES 
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for 
clinicians. 2016;66(1):7-30. 
2. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad 
M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 
1997;15(3):938-946. 
3. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, 
Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection 
for hepatic colorectal metastases. Annals of surgery. 2002;235(6):759-766. 
4. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey 
JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is 
associated with adoption of hepatic resection and improved chemotherapy. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 
2009;27(22):3677-3683. 
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-
Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de 
Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without 
oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 
2000;18(16):2938-2947. 
6. Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT. A 
'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced 
colorectal cancer. British journal of cancer. 2002;87(4):393-399. 
34 
 
7. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V, Lotz JP, 
Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M. Evaluation of oxaliplatin 
dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion 
regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology 
Multidisciplinary Research Group (GERCOR). Annals of oncology : official journal of the 
European Society for Medical Oncology / ESMO. 2000;11(11):1477-1483. 
8. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, 
Krulik M, Carola E, Izrael V, de Gramont A. CPT-11 (irinotecan) addition to bimonthly, 
high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for 
pretreated metastatic colorectal cancer. GERCOR. European journal of cancer. 
1999;35(9):1343-1347. 
9. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, 
Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting 
M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for 
metastatic colorectal cancer. The New England journal of medicine. 2009;360(14):1408-
1417. 
10. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky 
G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, 
Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III 
trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) 
versus FOLFOX4 alone as first-line treatment in patients with previously untreated 
metastatic colorectal cancer: the PRIME study. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 2010;28(31):4697-4705. 
11. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser 
M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with 
oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a 
35 
 
randomized phase III study. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2008;26(12):2013-2019. 
12. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, 
Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, 
Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F, 
Investigators RS. Ramucirumab versus placebo in combination with second-line 
FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after 
first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a 
randomised, double-blind, multicentre, phase 3 study. The Lancet. Oncology. 
2015;16(5):499-508. 
13. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, 
Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, 
Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of 
panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with 
FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 
2010;28(31):4706-4713. 
14. Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki 
A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E, Touroutoglou N, Chatzidakis A, 
Georgoulias V, Mavroudis D, Souglakos J. Front-line bevacizumab in combination with 
oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal 
cancer: a multicenter phase II study. BMC cancer. 2007;7:91. 
15. Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. 
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, 
including survival and subset analyses. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2011;29(28):3768-3774. 
36 
 
16. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski 
R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for 
panitumumab efficacy in patients with metastatic colorectal cancer. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 
2008;26(10):1626-1634. 
17. Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP, Simes J, 
Weickhardt A, Wrin JW, Wilson K, Gebski V, Van Hazel G, Robinson B, Cunningham D, 
Tebbutt NC. Correlation of extended RAS and PIK3CA gene mutation status with 
outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in 
combination with bevacizumab plus or minus mitomycin C in advanced colorectal 
cancer. British journal of cancer. 2015;112(6):963-970. 
18. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea 
S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, 
leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of 
metastatic colorectal cancer. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2009;27(5):663-671. 
19. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi 
B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile 
JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic 
factor in patients with advanced colorectal cancer treated with cetuximab. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 
2008;26(3):374-379. 
20. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes 
RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore 
MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal 
cancer. The New England journal of medicine. 2008;359(17):1757-1765. 
37 
 
21. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, 
Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, 3rd, Poplin 
EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ. Expression of epiregulin and 
amphiregulin and K-ras mutation status predict disease control in metastatic colorectal 
cancer patients treated with cetuximab. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 2007;25(22):3230-3237. 
22. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. The New 
England journal of medicine. 2009;361(1):98-99. 
23. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk 
S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, 
Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP, 
Investigators MCT. Addition of cetuximab to oxaliplatin-based first-line combination 
chemotherapy for treatment of advanced colorectal cancer: results of the randomised 
phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103-2114. 
24. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, 
Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, 
Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, 
Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-
Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, 
Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow 
TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations 
of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. 
25. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, 
Marshall CJ, Springer CJ, Barford D, Marais R, Cancer Genome P. Mechanism of 
activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 
2004;116(6):855-867. 
38 
 
26. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, 
Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T, Omata M. Functional 
analysis of mutations within the kinase activation segment of B-Raf in human colorectal 
tumors. Cancer research. 2003;63(23):8132-8137. 
27. Pritchard C, Carragher L, Aldridge V, Giblett S, Jin H, Foster C, Andreadi C, Kamata T. 
Mouse models for BRAF-induced cancers. Biochem Soc Trans. 2007;35(Pt 5):1329-
1333. 
28. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. 
Oncogene. 2007;26(22):3279-3290. 
29. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, 
Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over 
sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. 
Clinical colorectal cancer. 2014;13(3):164-171. 
30. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, 
Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of 
metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 
2011;117(20):4623-4632. 
31. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, 
Shivasami A, Cummins MM, Murone C, Tebbutt NC. Impact of KRAS and BRAF Gene 
Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine 
Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal 
Cancer. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2011;29(19):2675-2682. 
32. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, 
Slattery ML. Poor survival associated with the BRAF V600E mutation in microsatellite-
stable colon cancers. Cancer research. 2005;65(14):6063-6069. 
39 
 
33. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, 
Stathopoulos E, Georgoulias V, Souglakos J. BRAF mutations, microsatellite instability 
status and cyclin D1 expression predict metastatic colorectal patients' outcome. British 
journal of cancer. 2010;102(12):1762-1768. 
34. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, 
Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, 
Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, 
Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, Group B-S. Improved survival with 
vemurafenib in melanoma with BRAF V600E mutation. The New England journal of 
medicine. 2011;364(26):2507-2516. 
35. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, 
Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, 
Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, 
Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated 
with vemurafenib. The New England journal of medicine. 2012;366(8):707-714. 
36. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, 
Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. 
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated 
Colorectal Cancer. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology. 2015;33(34):4032-4038. 
37. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, 
Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, 
Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK 
Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 
2015;33(34):4023-4031. 
40 
 
38. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della 
Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-
Kenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes 
to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. 
Cancer discovery. 2012;2(3):227-235. 
39. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen 
RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) 
inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-103. 
40. Morris V. Circulating cell-free DNA as a marker for response and resistance to BRAF 
and EGFR inhibition in BRAF-mutated metastatic colorectal cancer. Paper presented at: 
AACR Molecular Targets2015. 
41. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon 
and rectal cancer. Nature. 2012;487(7407):330-337. 
42. Hendriks YM, de Jong AE, Morreau H, Tops CM, Vasen HF, Wijnen JT, Breuning MH, 
Brocker-Vriends AH. Diagnostic approach and management of Lynch syndrome 
(hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA: a cancer 
journal for clinicians. 2006;56(4):213-225. 
43. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, Thibodeau 
SN. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite 
instability. Cancer research. 1998;58(15):3455-3460. 
44. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, 
Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, 
Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW. CpG island 
methylator phenotype underlies sporadic microsatellite instability and is tightly 
associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787-793. 
41 
 
45. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, 
Konishi K, Hamilton SR, Issa JP. Integrated genetic and epigenetic analysis identifies 
three different subclasses of colon cancer. Proceedings of the National Academy of 
Sciences of the United States of America. 2007;104(47):18654-18659. 
46. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins 
genetics. Trends Genet. 2000;16(4):168-174. 
47. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21(2):163-167. 
48. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes 
premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 
1997;88(5):593-602. 
49. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces 
senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. 
Cell. 2008;132(3):363-374. 
50. Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M, Akashi H, Watanabe 
Y, Yamamoto H, Sasaki Y, Itoh F, Imai K, Sugai T, Shen L, Issa JP, Shinomura Y, 
Tokino T, Toyota M. IGFBP7 is a p53-responsive gene specifically silenced in colorectal 
cancer with CpG island methylator phenotype. Carcinogenesis. 2010;31(3):342-349. 
51. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui 
WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY. Similarity of the 
phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. 
Cancer research. 2002;62(22):6451-6455. 
52. Chan TL, Zhao W, Leung SY, Yuen ST, Cancer Genome P. BRAF and KRAS mutations 
in colorectal hyperplastic polyps and serrated adenomas. Cancer research. 
2003;63(16):4878-4881. 
53. Miyaki M, Konishi M, Kikuchi-Yanoshita R, Enomoto M, Igari T, Tanaka K, Muraoka M, 
Takahashi H, Amada Y, Fukayama M, et al. Characteristics of somatic mutation of the 
42 
 
adenomatous polyposis coli gene in colorectal tumors. Cancer research. 
1994;54(11):3011-3020. 
54. Kahn M. Can we safely target the WNT pathway? Nature reviews. Drug discovery. 
2014;13(7):513-532. 
55. Giannakis M, Hodis E, Jasmine Mu X, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena 
G, Lawrence MS, Qian ZR, Nishihara R, Van Allen EM, Hahn WC, Gabriel SB, Lander 
ES, Getz G, Ogino S, Fuchs CS, Garraway LA. RNF43 is frequently mutated in 
colorectal and endometrial cancers. Nat Genet. 2014;46(12):1264-1266. 
56. Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, 
Mohammed S, Heck AJ, Maurice MM, Clevers H. Tumour suppressor RNF43 is a stem-
cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488(7413):665-
669. 
57. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, 
Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJ, Stinson J, Gnad F, 
Huntley MA, Degenhardt JD, Haverty PM, Bourgon R, Wang W, Koeppen H, Gentleman 
R, Starr TK, Zhang Z, Largaespada DA, Wu TD, de Sauvage FJ. Recurrent R-spondin 
fusions in colon cancer. Nature. 2012;488(7413):660-664. 
58. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103(2):311-
320. 
59. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in 
colorectal cancer. Nat Rev Cancer. 2001;1(1):55-67. 
60. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev. 1999;9(1):15-
21. 
61. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, 
and diseases. Dev Cell. 2009;17(1):9-26. 
43 
 
62. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng 
D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, 
Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, 
McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, 
Carey TE, Vanasse G, Harris JL. Targeting Wnt-driven cancer through the inhibition of 
Porcupine by LGK974. Proceedings of the National Academy of Sciences of the United 
States of America. 2013;110(50):20224-20229. 
63. Taylor SM, Jones PA. Mechanism of action of eukaryotic DNA methyltransferase. Use of 
5-azacytosine-containing DNA. J Mol Biol. 1982;162(3):679-692. 
64. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty 
R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, 
Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin 
SB, Zahnow CA. Transient low doses of DNA-demethylating agents exert durable 
antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 
2012;21(3):430-446. 
65. Sharp AJ, Stathaki E, Migliavacca E, Brahmachary M, Montgomery SB, Dupre Y, 
Antonarakis SE. DNA methylation profiles of human active and inactive X chromosomes. 
Genome Res. 2011;21(10):1592-1600. 
66. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal 
cancer. The New England journal of medicine. 2009;361(25):2449-2460. 
 
  
44 
 
VITA 
Van Karlyle Morris II was born on July 26, 1980 in Memphis, Tennessee, the son of Van Karlyle 
Morris and Tessa Ann Morris.  After completing high school from Memphis University School in 
May 1998, he entered the University of North Carolina at Chapel Hill.  He graduated with a 
Bachelor of Sciences degree in Chemistry with Highest Honors in May 2002.  For two years, he 
worked as a research technician in the Department of Structural Biology at St. Jude Children’s 
Research Hospital in Memphis, Tennessee.  In August 2004, he enrolled in medical school at 
the University of Tennessee Health Sciences Center.  Upon earning his Doctorate of Medicine 
in May 2008, he then trained in Internal Medicine for residency at Duke University until June 
2011.  After residency, he completed his fellowship in Hematology/Oncology at the University of 
Texas – MD Anderson Cancer Center in June 2014.  Since that time, he has been a faculty 
member at the MD Anderson in the Department of Gastrointestinal Medical Oncology, where he 
is currently an Assistant Professor. 
 
